Luana Palazzi, Antonella Pasquato, Mattia Vicario, Alexandre Roulin, Patrizia Polverino de Laureto, Laura Cendron
Journal of peptide science : an official publication of the European Peptide Society 2020 NovPeptides are attractive drugs because of their specificity and minimal off-target effects. Short half-lives are within their major drawbacks, limiting actual use in clinics. The golden standard in therapeutic peptide development implies identification of a minimal core sequence, then modified to increase stability through several strategies, including the introduction of nonnatural amino acids, cyclization, and lipidation. Here, we investigated plasma degradations of hormone sequences all composed of a minimal active core peptide and a C-terminal extension. We first investigated pro-opimelanocortin (POMC) γ2/γ3-MSH hormone behavior and extended our analysis to POMC-derived α-melanocyte stimulating hormone/adrenocorticotropic hormone signaling neuropeptides and neurotensin. We demonstrated that in all the three cases analyzed in this study, few additional residues mimicking the natural sequence alter both peptide stability and the mechanism(s) of degradation of the minimal conserved functional pattern. Our results suggest that the impact of extensions on the bioactivity of a peptide drug has to be carefully evaluated throughout the optimization process. © 2020 European Peptide Society and John Wiley & Sons, Ltd.
Luana Palazzi, Antonella Pasquato, Mattia Vicario, Alexandre Roulin, Patrizia Polverino de Laureto, Laura Cendron. C-terminal tails mimicking bioactive intermediates cause different plasma degradation patterns and kinetics in neuropeptides γ-MSH, α-MSH, and neurotensin. Journal of peptide science : an official publication of the European Peptide Society. 2020 Nov;26(11):e3279
PMID: 32812282
View Full Text